and last year it was joined by Travere Therapeutics' Filspari (sparsentan), which is in the same class as atrasentan. Previously, the standard treatment was broad-spectrum immunosuppressant drugs ...
Last year it was joined by Travere Therapeutics' endothelin antagonist Filspari (sparsentan) and a few weeks ago by Novartis' oral complement factor B inhibitor Fabhalta (iptacopan). Meanwhile ...
After hours: March 24 at 7:14:10 PM EDT Loading Chart for TVTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback